Open Account
Demo Account
About Us
Real-time Quotes & News
Market Analysis
Economic Calendar
Daily Market Analysis
Trading Platform
Platform Overview
How To Use
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
繁
简
EN
User Login
Open Account
Demo Account
繁
简
EN
User Login
Open Account
Demo Account
About Us
About Aspire
Features of Aspire
Real-time Quotes & News
Real-time Quotes
Real-time News
Market Analysis
Economic Calendar
Market Analysis
Trading Platform
Meta Trader 5
Platform Features
Terms
All Terms
Deposit & Withdrawal
Promotion
FAQ
Contact
About Us
Terms
Metals Market
Trading Platform
Market Analysis
Promotion
FAQ
Contact
繁
简
EN
Israeli media report an assessment that, despite Trump's efforts to restrain Iran's response, Iran will still launch an attack.
2026-06-15
Israeli media report an assessment that, despite Trump's efforts to restrain Iran's response, Iran will still launch an attack.
Back
Other News
2026-06-15
A statement said HEZBOLLAH welcomed a US-Iran memorandum of understanding.
A statement said HEZBOLLAH welcomed a US-Iran memorandum of understanding.
2026-06-15
Novo Nordisk (NVO.N) said the world’s first and currently only approved weekly basal insulin/GLP‑1 receptor agonist, icodec/semaglutide injection, has launched in China. The product is approved for adults with type 2 diabetes whose blood glucose rema
Novo Nordisk (NVO.N) said the world’s first and currently only approved weekly basal insulin/GLP‑1 receptor agonist, icodec/semaglutide injection, has launched in China. The product is approved for adults with type 2 diabetes whose blood glucose remains uncontrolled on basal insulin or a GLP‑1 RA, to be used with oral glucose‑lowering drugs alongside diet and exercise.
Chat with us
, powered by
LiveChat